人精氨酸酶在毕赤酵母的高效表达、纯化和活性研究

目的：人精氨酸酶（Arginase, Arg）的基因arg在毕赤酵母高效分泌表达,建立相应纯化工艺路线,研究重组人精氨酸酶的活性。方法：将人精氨酸酶基因arg按正确的阅读框架插入到毕赤酵母表达载体pPIC9α信号肽基因后,构建得到重组毕赤酵母表达质粒。转化毕赤酵母GS115筛选高表达菌株。结果：成功构建了酵母表达载体pPIC-Arg,转化毕赤酵母GS115后筛选到分泌表达目的蛋白Arg的菌株,目标蛋白可以分泌到培养基中。经过膜过滤和凝胶过滤层析对培养基上清进行纯化,即可获得纯度达到95%的活性产物。活性测定表明,纯化的Arg比活性为310 IU/mg。结论：成功构建了Arg的毕赤酵母高效表达菌种,建立了目标物质的分离纯化工艺。     

HBsAg/GM-CSF融合蛋白在毕赤酵母中的表达及其免疫原性研究

为探索一种提高乙肝病毒表面抗原免疫原性的新方法,用PCR和基因重组技术构建HBsAg与GM-CSF的融合基因,并在毕赤酵母中分泌表达HBsAg/GM-CSF(S-GM)融合蛋白。表达产物用SDS-PAGE检测,W estern b lot分析,离子交换柱纯化后免疫昆明鼠,ELISA检测免疫小鼠血清中抗HBsAg的抗体水平。结果显示S-GM融合蛋白在毕赤酵母中获得了表达,离子交换柱一步纯化即可得到纯度达90%以上的S-GM。W estern b lot分析S-GM可分别与抗HBsAg及抗GM-CSF的抗体特异结合。ELISA检测发现第一次免疫后4w出现抗HBsAg的抗体,加强免疫后融合蛋白组几乎全部阳转,且抗体水平较HBsAg组(P=0.009<0.05)及HBsAg和GM-CSF的混合物组(P=0.032<0.05)高。HBsAg/GM-CSF融合蛋白能够在毕赤酵母中表达,且可增强HBsAg的免疫原性,为提高乙肝疫苗的免疫效果提供了新的思路与方法。     

毕赤酵母分泌表达JEV prME蛋白及其形成病毒样颗粒的免疫原性鉴定

应用毕赤酵母分泌表达日本脑炎病毒(Japanese encephalitis virus,JEV)prME蛋白,鉴定其表达效果与免疫原性,以期为JEV亚单位疫苗的研制奠定基础。RT-PCR扩增JEV SA14-14-2株prME基因,将其连接到毕赤酵母表达载体pPICZa-A,分别获得pPICZa-prME和携带JEV Cap蛋白C末端19个Aa信号肽的pPICZa-SprME质粒。表达载体用PmeⅠ酶切线性化,通过电转化转入毕赤酵母X33并诱导发酵培养。利用SDS-PAGE和Western blotting鉴定酵母发酵上清中目的蛋白的表达情况。利用GE蛋白层析纯化柱纯化目的蛋白,利用电镜观察纯化前后的目的蛋白,将不同剂量纯化后的prME蛋白与弗氏佐剂混合以及定量纯化后的prME蛋白与不同剂量的核酸佐剂混合分别免疫4周龄小鼠,定期采血,ELISA检测被免小鼠血清的抗体水平,空斑减少试验测定抗体中和效价。SDS-PAGE结果表明毕赤酵母可以分泌表达完整的prME蛋白,目的蛋白在70–100 kDa之间;Western blotting结果显示分泌表达的prME蛋白具有良好的反应原性,进一步证明prME蛋白在酵母X33中以整体的形式分泌表达,没有发生水解切割。纯化目的蛋白,根据洗脱时间和体积表明其分子量大于1×10~6 Da,因此推断prME蛋白可能形成多聚化的颗粒。电镜观察发现直径30–50 nm的病毒样颗粒(Virus like particles,VLPs)。免疫试验结果表明,纯化后的重组蛋白10–15μg/只接种小鼠在3周后抗体达到高峰值,之后逐渐下降,免疫7周后小鼠血清仍可检测到JEV抗体。将prME VLPs以10μg/只的剂量与不同剂量的核酸佐剂配伍后接种小鼠,ELISA检测结果表明核酸佐剂可明显增强JEV prME VLPs免疫应答,免疫4周后小鼠血清的中和抗体效价为1∶80–1∶160。上述结果表明毕赤酵母表达JEV prME虽不能发生水解切割,但仍可形成VLP并诱导免疫小鼠产生较高水平中和抗体。     

基因工程乙肝新型疫苗（汉逊酵母表达系统）的开发

HBsAg不同成份在多条生物细胞系统中已表达成功,但至今仅哺乳动物细胞（CHO,C127等）和酿酒酵母表达系统占领了大部分市场,我们的临床观察也证明了酵母重组疫苗对HBeAg和HBsAg双阳性母亲所生的新生儿免疫保护效果最好,近年来又发展了汉逊酵母表达系统,其特点为30个adw2HBsAg基因拷贝整合于该酵母染色体中,含有MOX,FMD等高效启动子,能利用甘油,甲醇为能量为源进行高密度发酵,每升发酵液的细胞干重达100g以上,工程菌发酵生产稳定性好,HBsAg颗粒表达最达400ug/ml,最终纯化的HBsAg达60ug/ml, 其单位产量比酿酒酵母表达系统高约10倍,小鼠实验证明该系统表达的HBsAg诱导体液和细胞免疫应答较好,值得开发出产品,适合于我国广大农村使用,在发展基因工程乙肝疫苗时也应考虑研究增强抗原细胞免疫工程菌的构建和疫苗佐剂。     

人SM22α在巴斯德毕赤酵母中的表达、纯化及抗体制备

目的：用酵母表达重组人平滑肌22α（SM22α）蛋白,制备兔抗人SM22α多克隆抗体。方法：利用PCR从pGEM3z—SM22α质粒扩增得到人SM22α基因编码区,重组至pPIC9构建酵母表达载体,转染巴斯德毕赤酵母,进行分泌型表达。表达产物经分步盐析和CM-纤维素柱层析纯化后,免疫家兔,制备兔抗人sM22α多克隆抗体。结果：所构建的pPIC9-SM22α酵母表达载体转染酵母感受态细胞后,外源性SM22α可整合至酵母染色体中,经甲醇诱导84h,可实现SM22α的高效表达与分泌。用70％硫酸铵处理上清液,收集沉淀进行离子交换层析纯化后,经变性的聚丙烯酰胺凝胶电泳（SDS-PAGE）可见一分子量为22kD的单一区带。用该纯化产物免疫家兔制备的兔抗人SM22α抗血清可用于检测人或大鼠血管壁中SM22α的表达水平。结论：重组人SM22α可在巴斯德毕赤酵母中进行高效表达与分泌,纯化蛋白可用于抗体制备,为研究SM22α功能提供了检测工具。     

人胰高血糖素样肽-1与人血清白蛋白融合蛋白在毕赤酵母中的表达

目的：在巴斯德毕赤酵母中表达有降糖活性的人胰高血糖素样肽-1（hGLP-1）突变体（2Gly-hGLP-1）与人血清白蛋白（HSA）的融合蛋白。方法：为将GLP-1氨基酸序列第2位的丙氨酸（Ala）定点突变为甘氨酸（Gly）,根据毕赤酵母偏爱密码子合成编码2Gly-hGLP-1的基因;采用重叠PCR法拼接2Gly-hGLP-1和HSA的基因,使得2Gly-hGLP-1的C端与HSA的N端通过甘氨酸五肽接头连接;将该融合基因插入表达载体pPIC9构建为重组载体pPIC9/2Gly-hGLP-1-HSA,电击转化至毕赤酵母GS115细胞,通过表型筛选和诱导表达实验获得高效表达菌株;工程菌在5L发酵罐中培养后,对发酵产物进行分离纯化和生物学活性分析。结果：融合蛋白在5L发酵罐中的表达量约为200mg/L,经纯化后纯度可达95%以上;小鼠糖耐量实验表明该融合蛋白具有明显的控血糖活性。结论：在毕赤酵母中分泌表达的融合蛋白2Gly-hGLP-1-HSA具有降血糖活性。     

重组人小分子抗体ScFv-Fc发酵条件的优化及纯化

目的：研究重组人小分子抗体ScFv—Fc在毕赤酵母中分泌表达的最佳条件,以及ScFv—Fc的纯化方法。方法：分别从甲醇浓度、pH、诱导时间等方面对毕赤酵母重组菌株产生ScFv-Fc的发酵过程进行了优化;通过硫酸铵沉淀结合proteinA亲和层析柱,对ScFv—Fc的纯化方法进行了研究。结果：确定ScFv—Fc在毕赤酵母中分泌表达的最佳条件为：在pH5．2的条件下,以0．5％甲醇诱导72h。经过proteinA亲和层析柱纯化后,ScFv—Fc纯度可达94％以上。结论：确定了ScFv-Fe在毕赤酵母中分泌表达的最佳条件以及纯化方法,为重组抗体分子诊断、治疗试剂的开发以及抗体的人源化奠定了物质基础。     

苹果蔗糖载体蛋白MdSUT1多克隆抗体的制备及MdSUT1蛋白表达特异性分析

高等植物光合同化产物蔗糖的质外体运输主要是靠蔗糖载体蛋白来完成的。MdSUT1是从苹果果实中克隆的蔗糖载体家族基因,本文将MdSUT1构建到酵母表达载体pMETαB,重组质粒转化毕赤酵母PMAD16经0．5％甲醇诱导后获得Md—SUT1表达。纯化的MdsuT1异源表达蛋白免疫Balb／C小鼠制备多克隆抗体,抗体特异性分析结果显示该抗体对酵母表达和苹果中的MdsuT1识别具有较高的特异性。免疫共沉淀实验结果也证明抗体能够应用于苹果果实中MdSUT1的功能分析。     

重组抗癫痫肽二串体的表达、纯化与鉴定

目的：利用基因工程方法表达抗癫痫肽（AEP）串联体蛋白,并进行纯化、鉴定。方法：PCR扩增AEP及AEP—His基因片段,并分别克隆至测序载体中;测序正确后,利用基因重组技术获得二串体基因,构建毕赤酵母表达载体pPIC9K-AEP2-His,甲醇诱导AEP2-His在毕赤酵母中表达,用Ni—chelating SepharoseFF柱纯化表达的融合蛋白,并用抗His单克隆抗体进行Westernblot鉴定。结果：构建了AEP二串体酵母表达载体,获得了纯化的AEP2-His蛋白,其相对分子质量约20000。结论：用基因串联思路表达小分子多肽是一种可行的方法;AEP2-His蛋白的成功表达为其功能研究奠定了基础。     

靶向性DNA甲基化酶在毕赤酵母中的表达和鉴定

目的：在毕赤酵母中表达融合Myc—His标签的靶向性甲基化酶B1—3a并进行鉴定。方法：以含有B1—3a基因的pcDNA4．0-myc／his质粒为模板,通过PCR扩增获得融合有myc／his标签序列的目的区段B1—3a基因,然后克隆入表达载体pPIC3-5k;电穿孔转化毕赤酵母菌株GS115,经G418筛选后进行甲醇诱导表达,并以SDS—PAGE和Western印迹对表达产物进行鉴定。结果：表达产物中可见与目的蛋白相对分子质量（50000）相符的条带,该条带可被Myc标签单克隆抗体特异识别。结论：正确构建了靶向性甲基化酶Bl-3a的酵母表达载体,靶向性甲基化酶能够在毕赤酵母中成功表达。     

聚乙二醇伴随式离子交换层析分离重组乙肝病毒表面抗原

对由中国仓鼠卵巢细胞(CHO)表达的多聚亚基蛋白HBsAg在离子交换层析过程中容易因亚基解离而导致蛋白解聚和丧失生物活性的难题,实验中选择聚乙二醇（PEG）作为保护剂伴随式（Polyethylene Glycol-Accompanied）离子交换层析分离纯化HBsAg。实验表明,在流动相中加入1% PEG10000(W/V)作为纯化伴侣, HBsAg的回收率由55% 左右提高到80%以上,纯化倍数基本保持在12左右。对纯化产物进行SDS_PAGE分析表明,1% PEG10000的纯化伴侣伴随式离子交换层析能全部保留HBsAg的糖基化蛋白单体（27kD和30kD）,高效液相色谱联用多角度激光散射(High Performance Size Exclusion Chromatography_Multiangle Laser Light Scattering, HPSEC-MALLS )进一步分析阐明了PEG能促使HBsAg颗粒尺寸分布更均一,结构更接近天然乙肝表面抗原。     

一种乙肝表面抗原结合蛋白可作为疫苗佐剂

乙肝表面抗原结合蛋白(HBsAg binding protein, SBP)是本实验室发现的一种可以与乙肝表面抗原HBsAg特异性结合的人源蛋白,该蛋白已经被证实具有增强乙肝疫苗免疫效果的作用.目前,我们已经利用毕赤酵母表达系统获得了能够分泌表达SBP的毕赤酵母表达菌株.本研究通过对上述菌株的发酵产物进行超滤和亲和层析纯化,获得了一定量的高纯度重组SBP蛋白,并利用酶联免疫吸附检测(ELISA)法和表面等离子体共振(SPF)法分别对重组SBP进行了体内外生物学活性的初步检测,证实其具有与HBsAg结合的能力,并求得了二者之间的亲和常数.将重组SBP作为乙肝疫苗增效剂与乙肝疫苗共同免疫小鼠,SBP增效组小鼠与对照组相比,血清中HBsAg抗体显著升高,表明SBP在体液免疫方面对乙肝疫苗具有显著的增效作用.上述结果表明,SBP有望作为乙肝疫苗的免疫佐剂,在乙型肝炎防治方面有重要意义.     

A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles

Spherical 22-nm hepatitis B surface antigen (HBsAg) particles with a subtype adr were purified from plasma of asymptomatic carriers of hepatitis B virus. When purified HBsAg preparation was treated with sodium dodecylsulfate in the absence of reducing agents, it yielded spherical particles with a diameter smaller than 22 nm, and in addition, a polypeptide with a molecular size of 49,000 daltons, which seemed to constitute the outer coat of HBsAg particles. The recovery of the polypeptide on the basis of optical density at 280 nm was 2%, starting from 22-nm HBsAg particles. The 49,000-dalton polypeptide apparently represented a structural unit of the surface of HBsAg particles, since it bore all common (a, Re) and subtypic (d, r) determinants with essentially the same antigenic titers as intact HBsAg particles. Furthermore, this polypeptide was equally immunogenic as 22-nm HBsAg particles in raising corresponding antibodies in mice. When the 49,000-dalton polypeptide was reduced in the presence of 2-mercaptoethanol, it cleaved into 22,000- and 27,000-dalton polypeptides with a drastic decrease in both antigenicity and immunogenicity. These results indicate the different molecular arrangements between outer coat and inner portion of HBsAg particles, and a potential application of the 49,000-dalton polypeptide as a component vaccine, owing to its strong antigenicity both in vitro and in vivo.     

A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart.

Semi-purified DEN-4 envelope protein, obtained in Pichia pastoris, was capable of generating neutralising and protecting antibodies after immunisation in mice. Here we compared two purification processes of this recombinant protein using two chromatographic steps: immune-affinity chromatography and immobilised metal ion adsorption chromatography (IMAC). The protein purified by both methods produced functional antibodies reflected by titres of haemagglutination inhibition and neutralisation. IMAC could be used as an alternative for high scale purification.     

Expression and purification of Dengue virus type 2 envelope protein as a fusion with hepatitis B surface antigen in Pichia pastoris

The methylotrophic yeast, Pichia pastoris, has been used as a host to express the envelope protein (Den2E) of dengue type 2 virus (NGC strain) as a chimera with hepatitis B surface antigen (HBsAg): a protein known to self assemble into virus-like particles (VLPs) and to be efficiently expressed in P. pastoris. The Den2E gene used in this study is a truncated version encoding the first 395 amino acid (aa) residues of the mature Den2E protein; the HBsAg gene encodes the full length 226 aa HBsAg protein. Two in-frame gene fusions were constructed for intracellular expression in P. pastoris. The first one contains the HBsAg gene as the 5' partner and the Den2E gene as the 3'partner (HBsAg-Den2E). In the second one, the relative positions of the two partners of the gene fusion were reversed to create the hybrid Den2E-HBsAg gene. These fusion genes were integrated into the genome of P. pastoris under the control of the methanol-inducible alcohol oxidase (AOX1) promoter. Of the two fusions, the Den2E-HBsAg gene was expressed at higher levels in P. pastoris based on Northern analysis. The hybrid protein ( approximately 68 kDa) expressed by this clone was purified to near homogeneity using a combination of acid precipitation, hydrophobic interaction, and immunoaffinity chromatographic steps. Final purification achieved was approximately 1400-fold with a yield of approximately 26%. The chimeric protein was found to possess the ability to assemble into high molecular weight aggregates (akin to HBsAg particles). The recombinant fusion protein eluted close to the void volume of a Sepharose CL-4B column indicating its macromolecular nature. On a CsCl density gradient the recombinant fusion protein sedimented to a position very similar to that of HBsAg VLPs. The hybrid protein is recognized by the two neutralizing monoclonals against the two components of the chimeric protein.     

Expression, purification and characterization of the Hepatitis B virus entire envelope large protein in Pichia pastoris

The current HBsAg vaccine has performed a vital role in preventing the transmission of HBV during the past 20 years. However, a number of individuals still show no response or a low response to the vaccine. In the present study, the HBV envelope large protein gene was cloned into the eukaryotic expression vector pPIC9k and was subsequently expressed in the yeast Pichia pastoris. The HBV large protein (L protein) was produced and secreted into the medium, where some of the L protein formed particles. The soluble L protein and particles were purified by column chromatography and sucrose density gradient centrifugation. Western blot analysis demonstrated that the particle was composed of both HBV L and S protein. To compare the antigenicity of the L protein and HBsAg, rabbits were immunized with the soluble L protein and the commercially available HBV vaccine and the increasing level of antibodies was determined by ELISA. The results showed that the anti-HBsAg antibody, from rabbits injected with the L protein at a dose of 2 and 10microg, was detected on day 14, whereas rabbits vaccinated with 10 and 2microg HBsAg did not develop antibodies until day 21 and 28, respectively. The antibody level in groups inoculated with the L protein was approximately 50% higher than in the group injected with HBsAg using the same dose. Furthermore, 2microg L protein induced a significant and rapid anti-HBsAg antibody response than 10microg HBsAg. Therefore, we suggest that the L protein is an ideal candidate for a new generation HB vaccine to protect people from HBV infection.     

Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris

Two human papillomavirus (HPV) prophylactic vaccines are currently available in the market: Gardasil and Cervarix. These two vaccines work against tumor high-risk subtypes HPV 16 and HPV 18. However, they do not include other high-risk subtypes such as HPV 58. Epidemiological research in China shows that HPV 58 is a prevalent high-risk subtype, second only to HPV 16 and HPV 18. Thus, for cervical cancer prevention in China, developing a vaccine against HPV 58 is necessary. In this study, HPV 58 virus-like particles (VLPs) were expressed in the Pichia pastoris, and subsequently purified through pretreatment and a three-step purification process consisting of strong cation exchange chromatography, size-exclusion chromatography, and hydroxyapatite chromatography. The highly purified HPV 58 VLPs were confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, electron microscopy, dynamic laser scattering, and ultracentrifugation. The purified VLPs were used to immunize mice to test their ability to induce humoral immunity. Enzyme-linked immunosorbent assays were performed on the sera of the immunized mice and significantly high anti-HPV 58 VLP antibody titers were observed. The immunogenicity study demonstrates that the purified HPV 58 VLPs are HPV vaccine candidates.     

Expression and purification of active recombinant human bikunin in Pichia pastoris

Bikunin is a proteoglycan exhibiting broad-spectrum inhibitory activity against serine proteases and could potentially suppress tumor cell invasion and metastasis. Here, we have successfully expressed recombinant human bikunin (rh-bikunin) in the methylotrophic yeast Pichia pastoris and established the purification procedure. The cDNA encoding human bikunin was cloned by PCR and inserted into the expression vector pPICZαC. After expressed in shake flask, rh-bikunin was produced in an 80-L fermenter and purified by cation exchange chromatography and reverse phase chromatography. The rh-bikunin was active by trypsin inhibition test. The final expression levels were 55 mg/L and we got totally 1.44 g (5600 inhibitor units/mg) of purified rh-bikunin (purity is 95%) from 40 L of fermentation broth. The rh-bikunin consists of two forms with molecular masses of 24 and 21 kDa, respectively. Both forms were immunoreactive by Western blotting and N-terminals were correctly processed by amino-terminal sequencing. This study provided a new method for expression and purification of active rh-bikunin.